These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7958484)

  • 1. Safe and effective poxvirus vectors--NYVAC and ALVAC.
    Paoletti E; Tartaglia J; Taylor J
    Dev Biol Stand; 1994; 82():65-9. PubMed ID: 7958484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
    Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
    Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development.
    Moss B
    Dev Biol Stand; 1994; 82():55-63. PubMed ID: 7958483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC.
    Tartaglia J; Cox WI; Pincus S; Paoletti E
    Dev Biol Stand; 1994; 82():125-9. PubMed ID: 7958466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and use of canarypox vectored vaccines.
    Plotkin SA; Cadoz M; Meignier B; Méric C; Leroy O; Excler JL; Tartaglia J; Paoletti E; Gonczol E; Chappuis G
    Dev Biol Stand; 1995; 84():165-70. PubMed ID: 7796950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination.
    Taylor J; Tartaglia J; Rivière M; Duret C; Languet B; Chappuis G; Paoletti E
    Dev Biol Stand; 1994; 82():131-5. PubMed ID: 7958467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines.
    Welter J; Taylor J; Tartaglia J; Paoletti E; Stephensen CB
    J Virol; 2000 Jul; 74(14):6358-67. PubMed ID: 10864646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.
    Cox WI; Tartaglia J; Paoletti E
    Virology; 1993 Aug; 195(2):845-50. PubMed ID: 8337851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice.
    Konishi E; Kurane I; Mason PW; Shope RE; Ennis FA
    Virology; 1997 Jan; 227(2):353-60. PubMed ID: 9018134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poxvirus-based vectors as vaccine candidates.
    Pincus S; Tartaglia J; Paoletti E
    Biologicals; 1995 Jun; 23(2):159-64. PubMed ID: 7546658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor.
    Dénes B; Gridley DS; Fodor N; Takátsy Z; Timiryasova TM; Fodor I
    J Gene Med; 2006 Jul; 8(7):814-23. PubMed ID: 16634110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poxvirus-based vectors as vaccine candidates.
    Tartaglia J; Pincus S; Paoletti E
    Crit Rev Immunol; 1990; 10(1):13-30. PubMed ID: 2407263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poxviruses as vaccine vectors.
    Pastoret PP; Vanderplasschen A
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus.
    Sutter G; Moss B
    Dev Biol Stand; 1995; 84():195-200. PubMed ID: 7796954
    [No Abstract]   [Full Text] [Related]  

  • 19. NYVAC: a highly attenuated strain of vaccinia virus.
    Tartaglia J; Perkus ME; Taylor J; Norton EK; Audonnet JC; Cox WI; Davis SW; van der Hoeven J; Meignier B; Riviere M
    Virology; 1992 May; 188(1):217-32. PubMed ID: 1566575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
    Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
    J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.